Biogen (Nasdaq: BIIB) and Eisai, two drug firms with manufacturing facilities in Research Triangle Park, have struck a deal in which Biogen will take over some of Eisai’s business and absorb some 50 Eisai employees.

Financial terms were not disclosed.

The deal was announced early Wednesday.

Just last week, Biogen opened a new 190,000 square foot facility at its RTP campus.

Both firms have operated facilities in the Park for two decades.

The deal involves Biogen leasing a portion of the Eisai plant for the manufacturing of oral solid dose products. Biogen says it plans to use the space to produce drugs for both firms.

Biogen signed a 10-year lease and has the option to acquire the oral solid dose operation.

“We view our supply chain as a lifeline to patients, designed to deliver quality therapies wherever and whenever they are needed,” said John Cox, executive vice president of Pharmaceutical Operations and Technology, for Biogen, in a statement. “This innovative capacity-sharing relationship with Eisai fits strategically in our global drug supply network, particularly as we advance our oral therapeutics.”

The employees involved with transfer to Biogen early in n2013, the companies said.

Biogen already employs some 1,000 people in the Triangle. Eisai says it has 225 workers.

“We look forward to collaborating with Biogen Idec to continue the proud history of drug manufacturing excellence here at our RTP site,” said Lou Arp, the general manager of the Eisai RTP site and president of Global Oncology Manufacturing, for Eisai. “Our alliance will enable both companies to focus on respective areas of expertise while continuing to deliver high-quality and innovative products to patients. Moreover, employees will benefit by working in a highly collaborative environment that offers opportunities to further cultivate their careers.”